home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences
Search  -  prev / next
 
 

Osteoarthritis Trials: The Role of Imaging for Subject Selection

 
  July 16, 2021  
     
 
Xtalks, Online
2021-07-28


The combination of an aging population and gains in longevity increases the significance and societal burden of osteoarthritis (OA). Bioclinica has worked actively in the application of imaging for OA clinical trials for more than 20 years, but a safe and effective disease-modifying therapy remains elusive. Nevertheless, interest in this disease remains high and pharmaceutical and biotech companies continue to discover and test new candidate therapies in hopes of solving this unmet medical need.

While a regulatory approval has not been achieved, advances in trial design and methods of evaluating biomarkers of interest have occurred, providing new confidence in running effective and efficient trials. One of the first challenges in designing an OA trial is selecting the right patient population to study. Clear clinical and imaging criteria have been established to diagnose the patient suffering from osteoarthritis. However, a successful trial will depend on more than that. Based on the candidate drug’s therapeutic target and method of action, the study population must also meet the endotype/phenotype requirements to maximize the chance to see a therapeutic effect. In addition, given the slowly evolving nature of this disease, careful subject selection can help shorten trial duration facilitating go/no-go and dose selection decisions.

It is now standard to use both radiography and MRI to select study participants who meet the baseline characteristics required by the trial design while excluding subjects with confounding conditions and other pathology. Moreover, imaging is shown to be useful for identifying an enriched cohort with increased risk of progression (e.g. radiographic joint space narrowing or cartilage loss).

Register for this webinar to explore the role of imaging in determining subject eligibility in OA trials. Topics to be covered will include:

  • The complementary roles of radiography and MRI for subject selection and when to use each
  • Specific selection criteria to target the right OA patients
  • Workflow strategies for efficient screening
  • The current status of prognostic imaging biomarkers for disease progression
 
 
Organized by: Xtalks
Invited Speakers:

Thomas Fuerst, PhD, Chief Science Officer, Bioclinica, Inc.

Ali Guermazi, MD, Professor of Radiology & Medicine, Boston University School of Medicine; President, Boston Imaging Core Lab

 

 
Deadline for Abstracts: -
 
Registration: Register at Xtalks.
E-mail: jozeph@xtalks.com
 
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2021 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.